Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Aug 1;6(8):e2331264.
doi: 10.1001/jamanetworkopen.2023.31264.

Naloxone Use in Novel Potent Opioid and Fentanyl Overdoses in Emergency Department Patients

Alexandra Amaducci  1 , Kim Aldy  2   3 , Sharan L Campleman  2 , Shao Li  2 , Alison Meyn  2 , Stephanie Abston  2 , Rachel E Culbreth  2 , Alex Krotulski  4 , Barry Logan  4   5 , Paul Wax  2   6 , Jeffrey Brent  7 , Alex F Manini  8   9 ; Toxicology Investigators Consortium Fentalog Study Group
Collaborators, Affiliations

Naloxone Use in Novel Potent Opioid and Fentanyl Overdoses in Emergency Department Patients

Alexandra Amaducci et al. JAMA Netw Open. .

Abstract

Importance: Synthetic opioids, such as the fentanyl analogue and nitazene drug class, are among the fastest growing types of opioids being detected in patients in the emergency department (ED) with illicit opioid overdose (OD). However, clinical outcomes from OD of novel potent opioids (NPOs), specifically nitazenes, are unknown aside from small case series.

Objective: To determine naloxone administration and clinical sequelae of patients who were in the ED with NPO overdose compared with fentanyl OD.

Design, setting, and participants: This is a cohort study subgroup analysis of adults admitted to the ED and tested positive for NPOs among in the ongoing nationwide ToxIC Fentalog cohort study from 2020 to 2022. Patients who were in the ED with a presumed acute opioid OD and residual blood samples were included, and those testing positive for NPOs were analyzed. Patients were included in this analysis if their confirmatory testing was positive for an NPO analyte, such as brorphine, isotonitazene, metonitazene, and/or N-piperidinyl etonitazene. A comparison group included patients that were positive for fentanyl and devoid of any other analytes on toxicologic analysis.

Exposures: Patients were exposed to NPOs, including brorphine, isotonitazene, metonitazene and/or N-piperidinyl etonitazene.

Main outcomes and measures: The primary outcome was the total number of naloxone doses and total cumulative naloxone dose administered as part of routine clinical care following the OD. Naloxone requirements and clinical sequelae of NPO-positive patients were compared with those testing positive for fentanyl only.

Results: During the study period, 2298 patients were screened, of whom 717 met inclusion criteria, 537 had complete laboratory testing data, with 11 (2.0%) positive for only fentanyl and 9 (1.7%) positive for NPOs (brorphine, isotonitazene, metonitazene, or N-piperidinyl etonitazene). The age range of patients was aged 20 to 57 years (4 males [44.4%] and 5 females [55.6%]). The NPO group received a statistically significantly higher mean (SD) number of naloxone boluses in-hospital (1.33 [1.50]) compared with the fentanyl group (0.36 [0.92]) (P = .02), which corresponded to a moderately large effect size (Cohen d = 0.78). Metonitazene overdose was associated with cardiac arrest and more naloxone doses overall. Metonitazene cases had a mean (SD) number of 3.0 (0) naloxone doses, and 2 of 2 patients (100%) with metonitazene overdoses were administered cardiopulmonary resuscitation.

Conclusions and relevance: In this cohort study of patients admitted to the ED with confirmed opioid overdose testing positive for NPOs, in-hospital naloxone dosing was high compared with patients who tested positive for fentanyl alone. Further study is warranted to confirm these preliminary associations.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Logan reported receiving personal fees from NMS Labs outside the submitted work. No other disclosures were reported.

Figures

Figure.
Figure.. Patient Eligibility and Groups
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Vandeputte MM, Van Uytfanghe K, Layle NK, St Germaine DM, Iula DM, Stove CP. Synthesis, chemical characterization, and μ-opioid receptor activity assessment of the emerging group of “nitazene” 2-benzylbenzimidazole synthetic opioids. ACS Chem Neurosci. 2021;12(7):1241-1251. doi:10.1021/acschemneuro.1c00064 - DOI - PubMed
    1. Center for Forensic Science Research and Education . ToxIC Fentalog Study Group—quarterly NPS report. Accessed March 27, 2023. https://www.cfsre.org/nps-discovery/clinical-reports
    1. Calello DP, Aldy K, Jefri M, et al. ; ToxIC Fentalog Study Group . Identification of a novel opioid, N-piperidinyl etonitazene (etonitazepipne), in patients with suspected opioid overdose. Clin Toxicol (Phila). 2022;60(9):1067-1069. doi:10.1080/15563650.2022.2084406 - DOI - PMC - PubMed
    1. Revisions to the standards for the classification of federal data on race and ethnicity. Federal Register. Accessed July 27, 2023. https://www.govinfo.gov/content/pkg/FR-1997-10-30/pdf/97-28653.pdf
    1. Moody MT, Diaz S, Shah P, Papsun D, Logan BK. Analysis of fentanyl analogs and novel synthetic opioids in blood, serum/plasma, and urine in forensic casework. Drug Test Anal. 2018;10(9):1358-1367. doi:10.1002/dta.2393 - DOI - PubMed

Publication types